DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist

@article{Perrella2018DAAsAL,
  title={DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist},
  author={PhD Alessandro Perrella and Luigi Rinaldi and Alfonso Galeota-Lanza and Antonio Izzi},
  journal={The American Journal of Gastroenterology},
  year={2018},
  volume={113},
  pages={1251-1266}
}
Dear Editor: We read with great interest the recently published Red Section entitled “The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong” by Kwo et al. [1]. Although we agree with the authors about an advisable universal access to these highly and effective DIrect Antiviral Agents (DAAs), we also believe it is important to underline that we still do not have any real-life long-term followup for these drugs. In fact, according to Cochrane review [2], the rates of hepatitis C… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-3 OF 3 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Direct-acting antivirals for chronic hepatitis C.

  • The Cochrane database of systematic reviews
  • 2017
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong

  • The American Journal of Gastroenterology
  • 2013
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL